Soyoun Min

Soyoun Min

Auto-generated profile, based on publicly available information

Soyoun Min

Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, OH 44195, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Immune Network
Verified
Journal Article
Open access
PDF file
YAYoko M. Ambrosini
Yoko M. Ambrosini
WSWoojung Shin
Woojung Shin
SMSoyoun Min
Soyoun Min
Hyun Jung KimHyun Jung Kim
Hyun Jung Kim
Ambrosini YM, et al. Immune Netw. 2020 Feb;20(2):e13. https://doi.org/10.4110/in.2020.20.e13

1 January 2009 in The Korean Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
HPHyun-Sil Park
Hyun-Sil Park
SCSeok-Goo Cho
Seok-Goo Cho
MPMin-Jung Park
Min-Jung Park
SMSo-Youn Min
So-Youn Min
HCHong-Seok Chang
Hong-Seok Chang
HKHo-Youn Kim
Ho-Youn Kim
Park HS, et al. Korean J Intern Med. 2009 Sep;24(3):252-262. http://dx.doi.org/10.3904/kjim.2009.24.3.252

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
YSYong Cheol Shin
Yong Cheol Shin
AWAlexander Wu
Alexander Wu
SMSoyoun Min
Soyoun Min
Dae-Sung KimDae-Sung Kim
Dae-Sung Kim
WSWoojung Shin
Woojung Shin
Hyun Jung KimHyun Jung Kim
Hyun Jung Kim
Immune checkpoint inhibitors (ICI) targeting PD-1, PD-L1, or CTLA-4 have shown remarkable therapeutic outcomes in various cancers. However, the therapeutic efficacy of ICI-based immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) has been extremely limited. Recent studies strikingly revealed that the human gut microbiome controls the efficacy of immune checkpoint blockades. Yet, the effect of the gut microbiome on reinforcing the ICI efficacy in MSS tumors in CRC is unknown. Here, we suggest a microengineered CRC Chip that recapitulates the tumor microenvironment of individual CRC patients by introducing biopsy-derived colonic organoid epithelium. We have built a three-dimensional (3D) lumen-capillary interface under peristalsis-like motions and flow in an oxygen-controlled microenvironment. We leverage this pathomimetic CRC Chip to recapitulate the patient-specific tumor-microbiome-immune axis to demonstrate microbial immunomodulation on the tumor cells and cytotoxic tumor immunity. We co-cultured various human intestinal bacteria in a CRC Chip to assess the immunomodulatory contribution to the tumor epithelium. We found that living Bifidobacterium sp. significantly reduces the PD-L1 on the tumor surface, followed by elevated anti-tumor activity after CD8 T cell-mediated cytotoxic interactions. We envision that our CRC Chip model can potentially reduce the knowledge gap between the bench and bedside. Furthermore, our innovative CRC Chip model may potentially offer a platform to validate the “Druggable microbiome” and the utility of the patient’s avatar model for Precision Medicine. Citation Format: Yong Cheol Shin, Alexander Wu, Soyoun Min, Daesung Kim, Woojung Shin, S. Gail Eckhardt, R. Y. Declan Fleming, Hyun Jung Kim. Microbial immunomodulation for enhancing immunotherapeutic efficacy in a patient-specific colorectal cancer chip [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3862.

18 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
SMSoyoun Min
Soyoun Min
HJHyeon-Su Jin
Hyeon-Su Jin
GKGrahame J Kidd
Grahame J Kidd
EBEmily Benson
Emily Benson
DLDong-Woo Lee
Dong-Woo Lee
Hyun Jung KimHyun Jung Kim
Hyun Jung Kim
Mechanobiological cues in the tissue microenvironment increasingly drive pathological fibroblast activation in inflammatory bowel disease (IBD), yet engineered platforms modeling this transition remain limited. Here, a microfluidic gut-on-a-chip microphysiological system and a mesofluidic rotary shaker are used to demonstrate that sustained fluid shear stress alone is necessary and sufficient to drive an irreversible, profibrotic phenotypic switch in primary normal human intestinal fibroblasts. Across both platforms, normal fibroblasts from small and large intestine reproducibly self-organize into three-dimensional (3D) multicellular aggregates within 72 h, independent of shear delivery format, indicating that the transition is governed by mechanical dose rather than device geometry. The resulting aggregates acquire robust α-smooth muscle actin (α-SMA) expression with aligned stress fibers, contrasting with the α-SMA-negative parental population. Scanning electron microscopy (SEM) resolves densely packed cellular microarchitecture embedded in a microfibrillar extracellular network, while ultrastructural serial block-face 3D EM reveals expansive intercellular spaces, stochastic fibrillar extrusions, and electron-dense cytoplasmic material at cell boundaries. Proteomic profiling confirms enrichment of core matrisome components, including collagen subtypes and matrix metalloproteinases. Together, these results establish fluid shear stress as a platform-independent, sufficient mechanical trigger for fibroblast-to-mechanoadaptive transition, positioning microphysiological shear platforms as tractable tools for modeling and targeting early fibrogenesis in IBD.